1021736-30-0Relevant articles and documents
Discovery of MK-5046, a potent, selective bombesin receptor subtype-3 agonist for the treatment of obesity
Sebhat, Iyassu K.,Franklin, Christopher,Lo, Michael M.-C.,Chen, David,Jewell, James P.,Miller, Randy,Pang, Jianmei,Palyha, Oksana,Kan, Yanqing,Kelly, Theresa M.,Guan, Xiao-Ming,Marsh, Donald J.,Kosinski, Jennifer A.,Metzger, Joseph M.,Lyons, Kathryn,Dragovic, Jasminka,Guzzo, Peter R.,Henderson, Alan J.,Reitman, Marc L.,Nargund, Ravi P.,Wyvratt, Matthew J.,Lin, Linus S.
, p. 43 - 47 (2011/04/17)
We report the development and characterization of compound 22 (MK-5046), a potent, selective small molecule agonist of BRS-3 (bombesin receptor subtype-3). In pharmacological testing using diet-induced obese mice, compound 22 caused mechanism-based, dose-
A practical, kilogram-scale implementation of the Wolff-Kishner reduction
Kuethe, Jeffrey T.,Childers, Karla G.,Peng, Zhihui,Journet, Michel,Humphrey, Guy R.,Vickery, Thomas,Bachert, Donald,Lam, Thientu T.
experimental part, p. 576 - 580 (2010/04/22)
A safe and practical strategy has been developed for the largescale preparation of imidazole 7. The key transformation involved the Wolff-Kishner reduction of the sterically demanding neopentyl- trifluoromethylcyclopropyl imidazole ketone 8. The described
